Inclusion Criteria:  Participant must be 18 to 75 years of age inclusive, at the time of signing the informed consent.  Participants who have  Impaired hepatic function according to Child-Pugh score A or B, Documented medical history of liver cirrhosis confirmed by either histopathology, laparoscopy, fibroscan, computer tomography, magnetic resonance imaging (MRI), or ultrasound, Stable impairment for at least 2 months prior to screening in the judgment of the investigator. Participants who have normal hepatic function and are overtly healthy. Body weight of at least 50 kg and BMI within the range 18 to 38 kg/m*2 (inclusive).  Male or female Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.  Male participants:  Male participants of reproductive potential must agree to use a condom (with or without spermicide) when heterosexually active. This applies for the time period between the signing of the informed consent form (ICF) until 7 days after the last dose of study intervention. Female partners of male participants do not need to follow special precautions. Female participants of childbearing potential: have to agree to use a highly effective non-hormonal contraception when heterosexually active. This applies for the time between signing the ICF until 21 days after the last dose of study intervention (for details and definitions of childbearing potential and allowed contraceptive methods). Female participants of childbearing potential must have a negative pregnancy test at screening and on Day -1. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.  Exclusion Criteria:  Ascites qualitatively estimated as severe or requiring acute or frequent paracentesis. Renal failure with an estimated glomerular filtration rate (eGFR) <= 40 mL/min according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. Encephalopathy of > grade 2. Renal failure with an eGFR <=60 mL/min CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation. Any clinically relevant disease (other than those related to hepatic impairment for the hepatic impaired participants) within 4 weeks prior to study drug administration including. Medically relevant infections and acute gastro-intestinal diseases (vomiting, diarrhea, constipation). Severe cerebrovascular or cardiovascular disorders less than 6 months prior to dosing, e.g., stroke, myocardial infarction, unstable angina pectoris, congestive heart failure of grade III or IV according to New York Heart Association (NYHA), arrhythmia requiring antiarrhythmic treatment, percutaneous transluminal coronary angioplasty or coronary artery bypass graft. Febrile illness within 1 week before first study drug administration.